Drugs in the Pipeline Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis By Brian Park, PharmD Publish Date April 13, 2022
News FDA Extends Shelf Life of Immune Globulin Products Asceniv and Bivigam By Brian Park, PharmD Publish Date March 30, 2022
Safety Alerts and Recalls Certain Immune Globulin Products Withdrawn Due to Higher Rate of Hypersensitivity Reactions By Brian Park, PharmD Publish Date March 9, 2022
Drugs in the Pipeline Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA By Brian Park, PharmD Publish Date January 28, 2022
Drugs in the Pipeline Novel Immunomodulator Gets Orphan Drug Status for Sarcoidosis By Brian Park, PharmD Publish Date January 6, 2022
News Orencia Approved for Prevention of Acute Graft Versus Host Disease By Brian Park, PharmD Publish Date December 16, 2021
News Cutaquig Approved for Pediatric Patients With Primary Humoral Immunodeficiency By Brian Park, PharmD Publish Date December 7, 2021
New Drug Products October 2021: 5 Notable Drug Approvals By Diana Ernst, RPh Publish Date November 11, 2021
News Potential Safety Concern for Guillain-Barré Syndrome ID’d for Ad26.COV2.S Publish Date October 19, 2021
Drugs in the Pipeline Cudetaxestat Gets Orphan Drug Status for Systemic Sclerosis By Brian Park, PharmD Publish Date October 15, 2021
News Rethymic Approved for Pediatric Congenital Athymia By Brian Park, PharmD Publish Date October 12, 2021
News Tavneos Approved for ANCA-Associated Vasculitis By Brian Park, PharmD Publish Date October 8, 2021
News Jakafi Approved for Chronic Graft-vs-Host Disease By Brian Park, PharmD Publish Date September 23, 2021
Safety Alerts and Recalls Ruzurgi Tablets Recalled Due to Yeast, Mold, Bacterial Contamination By Brian Park, PharmD Publish Date September 14, 2021
News Abatacept Gets Priority Review for Moderate to Severe Acute Graft vs Host Disease By Brian Park, PharmD Publish Date August 23, 2021